Research any topic before you write.
Find related topics. | Discover entities. | See connections. | Build a topical map.
Mirabegron, sold under the brand name Myrbetriq among others, is a medication used to treat overactive bladder. Its benefits are similar to antimuscarinic medication such as solifenacin or tolterodine. It is taken by mouth.
Research, Adverse effects & Overview
Explore the main themes, entities and connections around Mirabegron. Start with the topic map, then use the sections below for research and deeper semantic analysis.
Start with a few of the strongest sections from the source topic. These are research directions, not a list of keywords you must use.
High-confidence facts extracted from structured source data. Use them as anchors for further research.
Browse the full topic structure. Each item opens a new analysis centered on that subject.
Deeper signals for content research, entity SEO and topical coverage. The plain-language headings explain what each technical view is useful for.
See the strongest relationship patterns around the current topic before diving into the raw triples.
Use these terms to understand the vocabulary surrounding the topic, not as a checklist for keyword stuffing.
medication bladder effects overactive include urinary united liver mouth used adrenergic beta-3 side available use states medical cyp2d6 cyp3a4 solifenacin
| Subject | Predicate | Object | Confidence | Src |
|---|---|---|---|---|
| Mirabegron | 3D model (JSmol) | Interactive image | 1.00 | infobox |
| Mirabegron | AHFS/Drugs.com | Monograph | 1.00 | infobox |
| Mirabegron | ATC code | G04BD12 (WHO) | 1.00 | infobox |
| Mirabegron | Bioavailability | 29–35% | 1.00 | infobox |
| Mirabegron | CAS Number | 223673-61-8 | 1.00 | infobox |
| Mirabegron | ChEBI | CHEBI:65349 | 1.00 | infobox |
| Mirabegron | ChEMBL | ChEMBL2095212 | 1.00 | infobox |
| Mirabegron | ChemSpider | 8041219 | 1.00 | infobox |
| Mirabegron | CompTox Dashboard (EPA) | DTXSID101021648 | 1.00 | infobox |
| Mirabegron | DrugBank | DB08893 | 1.00 | infobox |
| Mirabegron | ECHA InfoCard | 100.226.392 | 1.00 | infobox |
| Mirabegron | Elimination half-life | 50 hours | 1.00 | infobox |
| Mirabegron | Excretion | Urine (55%), faeces (34%) | 1.00 | infobox |
| Mirabegron | Formula | C21H24N4O2S | 1.00 | infobox |
| Mirabegron | KEGG | D09535 | 1.00 | infobox |
| Mirabegron | Legal status | AU: S4 (Prescription only) | 1.00 | infobox |
| Mirabegron | Legal status | UK: POM (Prescription only) | 1.00 | infobox |
| Mirabegron | Legal status | US: ℞-only | 1.00 | infobox |
| Mirabegron | Legal status | EU: Rx-only | 1.00 | infobox |
| Mirabegron | Legal status | In general: ℞ (Prescription only) | 1.00 | infobox |
| Mirabegron | License data | US DailyMed: Mirabegron | 1.00 | infobox |
| Mirabegron | MedlinePlus | a612038 | 1.00 | infobox |
| Mirabegron | Metabolism | Liver via (direct) glucuronidation, amide hydrolysis, and minimal oxidative metabolism in vivo by CYP2D6 and CYP3A4. Some involvement of butylcholinesterase | 1.00 | infobox |
| Mirabegron | Molar mass | 396.51 g·mol−1 | 1.00 | infobox |
| Mirabegron | Other names | YM-178 | 1.00 | infobox |
| Mirabegron | Pregnancy category | AU: B3 | 1.00 | infobox |
| Mirabegron | Protein binding | 71% | 1.00 | infobox |
| Mirabegron | PubChem CID | 9865528 | 1.00 | infobox |
| Mirabegron | Routes of administration | By mouth | 1.00 | infobox |
| Mirabegron | Trade names | Myrbetriq, Betanis, Betmiga, others | 1.00 | infobox |
These clusters group vocabulary that occurs around closely connected concepts in the source material.
Bridges can reveal useful research angles that are easy to miss in a flat list of related terms.